FULCRUM THERAPEUTICS, INC. Operating Lease, Expense
FULCRUM THERAPEUTICS, INC. (FULC) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 40.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $500.00K, a 0.00% change year-over-year.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-12-31 was $500.00K, a 0.00% change year-over-year.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $500.00K, a 0.00% change year-over-year.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $1.90M, a 0.00% change from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $1.90M, a 0.00% change from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $1.90M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $300.00K S-4 · filed 2026-09-02 | $800.00 S-4 · filed 2026-09-02 | $800.00K 10-Q · filed 2026-07-30 | $1.30M derived: sum of 3 quarters · filed 2026-09-02 | $1.80M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-04-27 | $1.00M derived: sum of 2 quarters · filed 2026-09-02 | $1.50M derived: sum of 3 quarters · filed 2026-09-02 | $2.00M derived: sum of 4 quarters · filed 2026-09-02 | |
| 2025-12-31 | $500.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $1.00M derived: sum of 2 quarters · filed 2026-09-02 | $1.50M derived: sum of 3 quarters · filed 2026-09-02 | $1.90M S-4 · filed 2026-09-02 | |
| 2025-09-30 | $500.00K 10-Q · filed 2025-10-29 | $1.00M derived: sum of 2 quarters · filed 2025-10-29 | $1.40M 10-Q · filed 2025-10-29 | $2.00M derived: sum of 4 quarters · filed 2026-09-02 | |
| 2025-06-30 | $500.00K 10-Q · filed 2025-07-29 | $1.00M 10-Q · filed 2025-07-29 | $1.50M derived: sum of 3 quarters · filed 2026-09-02 | $2.00M derived: sum of 4 quarters · filed 2026-09-02 | |
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-01 | $1.00M derived: sum of 2 quarters · filed 2026-09-02 | $1.50M derived: sum of 3 quarters · filed 2026-09-02 | $2.00M derived: sum of 4 quarters · filed 2026-09-02 | |
| 2024-12-31 | $500.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $1.00M derived: sum of 2 quarters · filed 2026-09-02 | $1.50M derived: sum of 3 quarters · filed 2026-09-02 | $1.90M S-4 · filed 2026-09-02 | |
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-13 | $1.00M derived: sum of 2 quarters · filed 2024-11-13 | $1.40M 10-Q · filed 2024-11-13 | $2.10M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-06-30 | $500.00K 10-Q · filed 2024-07-31 | $1.00M 10-Q · filed 2024-07-31 | $1.60M derived: sum of 3 quarters · filed 2024-07-31 | $2.10M derived: sum of 4 quarters · filed 2024-07-31 | |
| 2024-03-31 | $500.00K 10-Q · filed 2024-05-13 | $1.10M derived: sum of 2 quarters · filed 2024-05-13 | $1.60M derived: sum of 3 quarters · filed 2024-05-13 | $2.10M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.10M derived: sum of 2 quarters · filed 2024-02-27 | $1.60M derived: sum of 3 quarters · filed 2024-02-27 | $1.90M 10-K · filed 2024-02-27 | |
| 2023-09-30 | $500.00K 10-Q · filed 2023-11-07 | $1.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.30M 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $500.00K 10-Q · filed 2023-08-03 | $900.00K 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $500.00K 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $1.90M 10-K · filed 2024-02-27 | ||||
| 2021-12-31 | $1.90M 10-K/A · filed 2023-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |